This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Uptravi

Actelion Pharmaceuticals Ltd.

Drug Names(s): ACT-293987, NS-304, selexipag

Description: Selexipag is an orally available long acting selective prostaglandin I2 (PGI-2) receptor agonist (also termed prostacyclin receptor, as PGI-2 is prostacyclin), which stimulates PGI-2 receptors in blood vessels and exerts vasodilating effects. Unlike prostacyclin analogs, selexipag is selective for the IP receptor over other prostanoid receptors.

Deal Structure: In February 2008, Actelion and Nippon Shinyaku (Nippon) announced the two companies have signed a binding letter of intent regarding NS-304, originally discovered and synthesized by Nippon Shinyaku. This binding letter of intent foresees that Actelion will be responsible for global development and commercialization of NS-304 outside Japan, whereas the two companies will co-develop and co-commercialize in Japan. Financial details were not disclosed.

On April 18, 2008, Actelion entered into an exclusive license agreement with Nippon on NS-304. Under the terms of the agreement between February 2008 and January 2010, Nippon received from Actelion upfront payments of USD 30 million (CHF 30.3 million), which have been expensed as R&D costs. Actelion will make further milestone payments depending on achievement of certain development and approval milestones and sales targets. If Actelion is successful in obtaining regulatory approval, Actelion will pay royalties to Nippon on a...See full deal structure in Biomedtracker

Partners: Nippon Shinyaku Co., Ltd.


Uptravi News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug